Tretinoin liposomal - HighField Biopharmaceuticals Corporation
Alternative Names: HF-1K16Latest Information Update: 17 Jul 2024
At a glance
- Originator HighField Biopharmaceuticals
- Class Antiacnes; Antineoplastics; Cyclohexenes; Keratolytics; Retinoids; Small molecules
- Mechanism of Action Myeloid-derived suppressor cell modulators; Protein synthesis inhibitors; Retinoic acid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes
Highest Development Phases
- Phase I/II Solid tumours
Most Recent Events
- 31 May 2024 Pharmacodynamics, adverse events and efficacy data from a phase I trial in Glioma presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
- 28 Apr 2024 No recent reports of development identified for phase-I development in Solid-tumours(In volunteers) in USA (IV, Injection)
- 23 Oct 2023 Updated safety and efficacy data from the phase Ia part of the phase Ib/II trial in Solid tumors was released by HighField Biopharmaceuticals